Drug Discovery News and Research

RSS
The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.
deCODE genetics completes sale of its Iceland-based subsidiary to Saga Investments

deCODE genetics completes sale of its Iceland-based subsidiary to Saga Investments

MDRNA to receive European patent for its intranasal insulin formulation

MDRNA to receive European patent for its intranasal insulin formulation

Growth of OMI equipment sales to reach $400M in 2014

Growth of OMI equipment sales to reach $400M in 2014

Dosing in First-in-Man Phase I study of 4SC AG's 4SC-203 commenced

Dosing in First-in-Man Phase I study of 4SC AG's 4SC-203 commenced

GSK to offer scientists access to compounds, lab space to fight malaria

GSK to offer scientists access to compounds, lab space to fight malaria

Xbrane Bioscience signs licensing arrangement with Vaxiion Therapeutics

Xbrane Bioscience signs licensing arrangement with Vaxiion Therapeutics

Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients

Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients

Varian announces the release of significant additions to its family of Pursuit LC columns

Varian announces the release of significant additions to its family of Pursuit LC columns

Fast Forward, JDRF announce collaborative partnership with Axxam SpA

Fast Forward, JDRF announce collaborative partnership with Axxam SpA

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

EMBL-EBI hosts drug discovery database

EMBL-EBI hosts drug discovery database

Scientists launch NEWMEDS project to develop drugs for schizophrenia and depression

Scientists launch NEWMEDS project to develop drugs for schizophrenia and depression

Boehringer Ingelheim, Priaxon announce collaboration in development of mdm2/p53 inhibitors for cancer

Boehringer Ingelheim, Priaxon announce collaboration in development of mdm2/p53 inhibitors for cancer

Babraham Institute research may lead to new means of making purified T cells

Babraham Institute research may lead to new means of making purified T cells

Sirnaomics certifies polypeptide nanoparticle technology

Sirnaomics certifies polypeptide nanoparticle technology

Metabolon awarded US Patent for ‘metabolomics methods’

Metabolon awarded US Patent for ‘metabolomics methods’

Sword Diagnostics launches Raman detection system for ultrasensitive immunoassays

Sword Diagnostics launches Raman detection system for ultrasensitive immunoassays

Era of rapid expansion in biomedical research funding began in 1990's ends

Era of rapid expansion in biomedical research funding began in 1990's ends

The Automation Partnership announces the US launch of Cell-IQ

The Automation Partnership announces the US launch of Cell-IQ

Scientists identify fast-acting compound to improve cognitive function impairments

Scientists identify fast-acting compound to improve cognitive function impairments

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.